Resumen
In this review, we provide a brief account of recent genomic findings, updated guidelines and emerging promising tools to help refine our diagnostic abilities in the setting of myelodysplastic neoplasms; We also discuss limitations of current practices during disease follow-up, to shed light on the pressing need to enhance our prognostic armamentarium in the near future.